AstraZeneca (AZN) stock in focus as its partner Daiichi Sankyo (DSNKY) wins EU backing for their jointly developed breast ...

Shares of newly public Metsera (NASDAQ:MTSR), which is developing ultra-long-acting obesity drugs, rallied 54% following a ...

FDA approved Ryoncil ® as the first and only therapy for pediatric patients 2 months and older, including adolescents and teenagers, with steroid-refractory acute graft versus host disease (SR-aGvHD), ...

Pharmaceutical company AstraZeneca on Friday cancelled a planned 450 million-pound ($560 million) investment in a vaccine manufacturing plant in northwest England, blaming the new Labour government ...

-- AstraZeneca has shelved a plan to build a vaccine manufacturing plant in Speke, near Liverpool, valued at 450 million pounds ($558.7 million), after months of talks with British government ...

Shares in Amazon ( AMZN) are up nearly 46% over the past year, with the stock hitting a record high closing price of $238.15 ...

Takeda is promoting U.S. chief Julie Kim to be its next CEO. AstraZeneca and Daiichi's Enhertu has won an FDA nod to expand into HER2-ultralow breast cancer. | Takeda is promoting U.S. chief Julie Kim ...

Tech stocks rallied as investors appeared reassured that there are fundamental reasons to be positive about the outlook. Atlassian surges.

Fast-changing news on tariffs flummoxed traders across asset classes Friday, shattering the calm spurred earlier by receding ...

As seen in the DESTINY-Breast06 trial, a pproximately 20-25 percent of hormone receptor (HR)-positive, HER2- ...

Stocks are ending a wild week on a positive note after solid forecasts from tech heavyweights eased concern about the outlook for the industry that has powered the bull market.

Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's ...